Increase in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells  by Ikari, Akira et al.
Biochimica et Biophysica Acta 1823 (2012) 1110–1118
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrIncrease in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung
adenocarcinoma A549 cells
Akira Ikari a,⁎, Tomonari Sato a, Ryo Watanabe a, Yasuhiro Yamazaki a, Junko Sugatani a,b
a Department of Pharmaco-Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
b Global Center of Excellence for Innovation in Human Health Sciences, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, JapanAbbreviations: ABCD, avidin–biotin conjugated D
active-EMK; ChIP, chromatin immunoprecipitation; D
MEK; EGF, epidermal growth factor; MMP, matrix m
small cell lung cancer; TJs, tight junctions; TGF, transfor
⁎ Corresponding author. Tel.: +81 54 264 5776; fax:
E-mail address: ikari@u-shizuoka-ken.ac.jp (A. Ikari)
0167-4889/$ – see front matter © 2012 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2012.04.005a b s t r a c ta r t i c l e i n f oArticle history:
Received 6 January 2012
Received in revised form 12 April 2012
Accepted 16 April 2012
Available online 24 April 2012
Keywords:
Claudin-2
Lung
Matrix metalloproteinase
Epidermal growth factor
c-FosIn human adenocarcinoma, claudin-2 expression is higher than that in normal lung tissue, but the regulatory
mechanism of its expression has not been clariﬁed. In human adenocarcinoma A549 cells, claudin-2 level
time-dependently increased under the control conditions. In contrast, claudin-1 expression remained constant
for 24 h. The concentration of epidermal growth factor (EGF) in medium time-dependently increased, which
was inhibited bymatrix metalloproteinase (MMP) inhibitor II, an inhibitor of MMP-1, 3, 7, and 9. MMP inhibitor
II decreased claudin-2 and phosphorylated ERK1/2 (p-ERK1/2) levels, which were recovered by EGF. Both
claudin-2 and p-ERK1/2 levels were decreased by EGF neutralizing antibody, EGF receptor (EGFR) siRNA,
AG1478, an inhibitor of EGFR, U0126, an inhibitor of MEK, and the exogenous expression of dominant
negative-MEK. These results suggest that EGF is secreted from A549 cells by MMP and increases claudin-2 ex-
pressionmediated via the activation of an EGFR/MEK/ERK pathway. The inhibition of the signaling pathway de-
creased phosphorylated c-Fos and nuclear c-Fos levels. The introduction of c-Fos siRNA decreased claudin-2 level
without affecting claudin-1. The promoter activity of human claudin-2 was decreased by AG1478 and U0126.
Furthermore, the activity was decreased by the deletion or mutation of the AP-1 binding site of claudin-2 pro-
moter. Chromatin immunoprecipitation and avidin–biotin conjugated DNA assays showed that c-Fos binds to
the AP-1 binding site. We suggest that a secreted EGF up-regulates the transcriptional activity of claudin-2 me-
diated by the activation of an EGFR/MEK/ERK/c-Fos pathway in A549 cells.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Human lung cancer is divided into two classes, small cell and non-
small cell lung cancer (NSCLC). NSCLC account for approximately 85%
of cases with lung cancer and is the leading cause of cancer-related
deaths in the world. More than 50% of NSCLC patients are candidates
for systemic treatment with chemotherapy. Epidermal growth factor
receptor (EGFR) is more abundantly expressed in lung carcinoma tis-
sue than in adjacent normal tissue [1]. Treatment with the EGFR ki-
nase inhibitors, geﬁtinib and erlotinib, causes tumor regression in
some patients with NSCLC [2]. EGFR-driven cell signaling contributes
to the unregulated progression and cancer malignancy. The strong in-
vasive and metastatic characteristics of lung cancer cells are responsi-
ble for the relatively high malignancy. The cell–cell adhesion system
is involved in the regulation of invasion and metastasis of cancer
cells, although the mechanism has not been fully clariﬁed.NA; CA-MEK, constitutively
N-MEK, dominant negative-
etalloproteinase; NSCLC, non-
ming growth factor
+81 54 264 5773.
.
l rights reserved.The cell–cell adhesion in epithelial and endothelial cells is formed by
tight junctions (TJs), adherens junctions, gap junctions, and desmosomes.
TJs are located at the apical pole of the lateral membrane and compose a
large complex of integral membrane, scaffolding, and signaling proteins
[3,4]. TJs separate the apical and basolateral epithelial compartments
and regulate the ﬂux of ions and solutes through the paracellular space,
cell proliferation, and cell differentiation [5–7]. Claudins and occludin
are tetraspanning proteins with cytoplasmic amino and carboxyl termini.
The carboxyl terminus has a PDZ-bindingmotif that can interact with the
PDZ domains of scaffolding proteins ZO-1, ZO-2, and ZO-3 [8–10].
Claudins comprise a large family of 27 members that form homo- and
heterotypic associations with each other [11–13]. Different combinations
of claudins can confer different properties to epithelial cells.
The alteration of claudin expression has been reported in tumors iso-
lated from lung, breast, ovary, pancreas, and colon tissues [14–17]. The ex-
pression of certain claudins affects the development as well as invasive
and migrative properties of cancer cells. Normal lung epithelia express
claudin-1, -3, -4, -5, -7, and ‐18, but do not express claudin-2, -6, -7, -9,
-11, -15, and ‐16 [18,19]. In patients with lung adenocarcinoma, low
claudin-1 expression has shorter overall survival [20]. Claudin-1 over-
expression inhibits cell migration, invasion, and metastatic colonization
in CL1–5 cells, a human lung adenocarcinoma cell line that lacks endoge-
nous claudin-1 expression. In lung cancer tissue microarrays, claudin-7
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tribution pattern compared to normal tissue [21]. Claudin-7 over-
expression inhibits cell migration and invasion in NCI-H1299, a human
NSCLC cell line that lacks endogenous claudin-7 expression.
In the present study, we found that claudin-2 expression in
human lung adenocarcinoma is higher than that in normal tissue
and other lung carcinoma. We and others recently reported that
claudin-2 enhances cell migration [22] and colonization [23] in
A549 cells derived from human adenocarcinoma. Claudin-2 may be
involved in the up-regulation of tumor cell motility. Therefore, we ex-
amined the regulatory mechanism of claudin-2 expression using
A549 cells. Epidermal growth factor (EGF) is secreted from A549
cells by matrix metalloproteinase (MMP) and the activation of an
EGFR/MEK/ERK pathway increases claudin-2 expression. c-Fos, a
down-stream target in an EGFR/MEK/ERK pathway, binds to the AP-
1 binding site of human claudin-2 promoter and enhances its tran-
scriptional activity. These results indicate that transcriptional activity
of claudin-2 is up-regulated by an EGFR/MEK/ERK/c-Fos pathway in
A549 cells.2. Materials and methods
2.1. Materials
The anti-claudin-1 and ‐2, occludin and ZO-1 antibodies were
obtained from Zymed Laboratories (South San Francisco, CA, USA). The
anti-E-cadherin antibody was from Becton Dickinson Biosciences (San
Jose, CA). The anti-phosphorylated-ERK1/2 (p-ERK1/2), c-Fos, phospho-
rylated c-Fos (p-c-Fos) and β-actin antibodies were from Santa Cruz Bio-
technology (Santa Cruz, CA). The anti-ERK1/2 and c-Jun antibodies were
from Cell Signaling Technology (Beverly, MA). The anti-phosphorylated
c-Jun (p-c-Jun) antibody was from Signalway Antibody (Pearland, TX).
The anti-nucleoporin p62 antibody was from Becton Dickinson Biosci-
ences (San Jose, CA). The anti-human EGF antibody was from R&D
systems (Minneapolis, MN). Alexa Fluor 488 and 543 conjugated anti-
bodies were from Molecular Probes (Eugene, OR). U0126 was from
Sigma-Aldrich (Saint Louis, MO). AG1478 was fromWako Pure Chemical
Industries (Osaka, Japan). MMP inhibitor II and MMP-2 inhibitor I were
from Merck-Calbiochem (Darmstadt, Germany). Lipofectamine 2000
was from Invitrogen (Carlsbad, CA). All other reagentswere of the highest
grade of purity available.2.2. Cell culture and transfection
A549, human lung adenocarcinoma, RERF-LC-AI, squamous cells,
IA-LM, large cells, and WA-hT, small cells, were obtained from the
RIKEN BRC through the National Bio-Resource Project of the MEXT,
Japan. Cells were grown in Dulbecco's modiﬁed Eagle's medium
(Sigma-Aldrich, Saint Louis, MO) supplemented with 5% fetal calf
serum (FCS, HyClone, Logan, UT), 0.07 mg/ml penicillin-G potassium,
and 0.14 mg/ml streptomycin sulfate in a 5% CO2 atmosphere at 37 °C.
Growth factors such as EGF and transforming growth factor were not
added to the FCS. A549 cells (passages 90–105) were treated with
various inhibitors in the FCS-free medium. HA-tagged constitutively
active-MEK (CA-MEK) or dominant negative-MEK (DN-MEK) vector
(Biomyx, San Diego, CA) was transfected into A549 cells with
Lipofectamine 2000 as recommended by the manufacturer.2.3. Preparation of cell lysates and immunoblotting
Preparation of cell lysates and immunoblotting were performed as
described previously [22]. Nuclear protein was isolated using NE-PER
nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientif-
ic, Rockford, IL).2.4. Measurement of EGF content
Medium was collected from the cells incubated in the presence
and absence of MMP inhibitors. EGF content was measured by
Human EGF ELISA kit (Ray Biotech, Norcross, CA) as recommended
by the manufacturer.
2.5. RNA isolation and quantitative RT-PCR
Three independent mRNAs of normal lung tissue were purchased
from Clontech laboratories (Mountain View, CA), Agilent Technolo-
gies (Santa Clara), and BioChain (Hayward, CA). Total RNA was isolat-
ed from A549, RERF-LC-AI, IA-LM and WA-hT cells using TRI reagent
(Sigma-Aldrich). Reverse transcription was carried out with M-MLV
reverse transcriptase (Promega, Madison, WI) and random primers.
To compare the expression level of claudin-2 between normal lung and
cancer tissues,weobtained LungCancer cDNAArray II andV fromOriGene
(Rockville, MD). Single strand cDNA was ampliﬁed by PCR using GoTaq
DNA polymerase under the following conditions: denaturation at 94 °C
for 0.5 min, annealing at 54 °C for 0.5 min, and extension at 72 °C for
0.5 min; these steps were repeated 30 cycles. Primers used in PCR were
5′-ATGAGGATGGCTGTCATTGG-3′ and 5′-ATTGACTGGGGTCATAGGGT-3′
(claudin-1), 5′-ATTGTGACAGCAGTTGGCTT-3′ and 5′-CTATAGATGTCAC-
ACTGGGTGATG-3′ (claudin-2), and 5′-CCTGAGGCACTCTTCCAGCCTT-3′
and 5′-TGCGGATGTCCACGTCACACTTC-3′ (β-actin). Quantitative real‐
time PCR was performed using SYBR Premix Ex Taq (Takara Bio, Tokyo,
Japan). The threshold cycle (Ct) for each PCR product was calculated
with the instrument's software, and Ct values obtained for claudin-1 and
‐2 were normalized by subtracting the ct values obtained for β-actin.
The resulting ΔCt values were then used to calculate the relative
change in mRNA expression as a ratio (R) according to the equation
R=2−(ΔCt(treatment)−ΔCt(control)) or 2−(ΔCt(cancer)−ΔCt(normal)).
2.6. Confocal microscopy
A549 cells were plated at a conﬂuent density on cover glasses. The
cells were ﬁxed with methanol for 10 min at −20 °C, then perme-
abilized with 0.2% Triton X-100 for 15 min. After blocking with 2%
Block Ace (Dainippon Sumitomo Pharma, Osaka, Japan) for 30 min,
the cells were incubated with anti-claudin-2 and ZO-1 antibodies
for 16 h at 4 °C. They were then incubated with Alexa Fluor 488 and
Alexa Fluor 543-conjugated antibodies for 1 h at room temperature.
Immunolabeled cells were visualized on an LSM 510 confocal micro-
scope (Carl Zeiss, Germany). Images were further processed using
Adobe Photoshop (Adobe System, San Jose, CA).
2.7. RNA interference
EGFR, c-Fos, and c-Jun siRNAs were produced by Sigma-Aldrich. The
oligoribonucleotides were 5′-CAAAGUGUGUAACGGAAUATT-3′ (EGFR
siRNA), 5′-CUGUCAACGCGCAGGACUUTT-3′ (c-Fos siRNA) and 5′-
CUGAUAAUCCAGUCCAGCATT-3′ (c-Jun siRNA). Cells were transfected
with these siRNAs or control siRNA (Fluorescein Conugate)-A (Santa
Cruz) using Lipofectamine 2000 as recommended by the manufacturer.
Immunoblotting was performed after 48 h of transfection.
2.8. Luciferase reporter assay
The promoter region of the human claudin-2 gene [NC_000023.10]
was subcloned into the pGL4.10(luc2) vector (Promega,Madison,WI) up-
stream of a luciferase reporter gene. The fragment of −1031/+37 was
ampliﬁed by PCR using a set of primer (sense, 5′-AGCCTGGGTGCCA-
AAG-3′) and (antisense, 5′-GCTGACTTCTCTCCTCCT-3′). The fragments
of −395/+37 and −60/+37 were ampliﬁed using primers of (sense,
5′-GTCTGCAGTTTGGCCTC-3′) and (sense, 5′-TTAATCTGGTTTATGG-3′),
respectively. A Renilla construct, pRL-TK vector (Promega), was used
Table 1
Characteristics of the patients.
No. of patients
Gender
Male 59
Female 31
Normal 12
Cancer types Stage
Adenocarcinoma I 21
II 8
III 12
IV 4
Squamous I 11
II 10
III 4
IV 1
Large I 2
II 1
III 1
Small I 1
III 2
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Fig. 1. High levels of claudin-2 in adenocarcinoma and A549 cells. (A) Lung cancer
cDNA array II and V contains 12, 45, 26, 4, and 3 samples of normal, adenocarcinoma,
squamous, large, and small cells, respectively. Quantitative real-time PCR was per-
formed using primers for claudin-2. β-actin served as an internal control. The ex-
pression of claudin-2 mRNA was expressed relative to the value in normal tissue.
(B) Three independent mRNAs of normal lung tissue (N) were obtained as described
in Materials and methods. A549, RERF-LC-AI (LC-AI), IA-LM, and WA-hT cells were
grown to conﬂuence. Total RNA was isolated from these cells and reverse transcribed
into cDNA. The expression of claudin-2 mRNA was expressed relative to the value in
the normal tissue. ** Pb0.01 compared with normal tissue.
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plasmid DNA using Lipofectamine 2000. After 48 h of transfection,
luciferase activity was assessed using the Dual-Glo Luciferase
Assay System (Promega). U0126 and AG1478 were added for the
ﬁnal 24 h before the luciferase assay. The luminescence of the Fireﬂy
and Renilla luciferase was measured with a Multilabel Counter 1420
ARVOsx (Perkin Elmer, Wellesley, MA). Relative promoter activity was
represented as the fold increase compared to the promoter‐less
pGL4.10 vector. The mutant of AP-1 binding site (−854/−847)
was generated using a Quick Change site-directed mutagenesis kit
(Stratagene, La Jolla, CA). The primer pair was 5′-CTGAGATTCCAAAG-
CATTAAAACAGATACCTGCCTCATGC-3′ (sense) and 5′-GCATGAGGCAG
GTATCTGTTTTAATGCTTTGGAATCTCAG-3′ (antisense).
2.9. Chromatin immunoprecipitation (ChIP) assay
A549 cells were treated with 1% formaldehyde to crosslink
the protein to the DNA. Then, ChIP assay was performed using
EZ ChIP Chromatin Immunoprecipitation Kit (Upstate Biotech, Lake
Placid, NY) as recommended by the manufacturer's instructions. To
co-immunoprecipitate the DNA, c-Fos and c-Jun antibodies were used.
The eluted DNA was ampliﬁed by PCR using the primer pairs −935S
(sense: 5′-CCCTTAGTGTCCTGAATCTTGG-3′) and −782A (antisense:
5′-AAGAGTCTGCCACAGAGGAAAG-3′) or−1538S (sense: 5′-GCCAGAT
TGTGGTGGGTTGA-3′) and −1387A (antisense: 5′-AGAGACCAGGTTT
TGCCATGT-3′). To conﬁrm the same amounts of chromatins used in im-
munoprecipitation between groups, input chromatinwas also used. The
PCR product (154 and 152 bp) was visualized with ethidium bromide
after electrophoretic separation on a 2% agarose gel. Immunoprecipita-
tion using goat IgG was carried out as a negative control.
2.10. Avidin–biotin conjugated DNA (ABCD) assay
The following double-stranded oligonucleotides were used. All
biotinylated at the 3′-end of the sense strand, wild-type AP-1: 5′-
GATTCCAAAGCATTGACTCAGATACCTGCC-3′, and mutant AP-1: 5′-
GATTCCAAAGCATTAAAACAGATACCTGCC-3′. An ABCD assay was per-
formed by incubating nuclear extracts derived from A549 cells with
double-stranded DNA immobilized on streptavidin agarose in a binding
buffer (80 mM KCl, 1 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol,
10% glycerol, 0.1% Triton X-100, 20 mMHepes-KOH (pH 7.9), a protease
inhibitor cocktail and 1 mM phenylmethylsulfonyl ﬂuoride). After 16 h
of incubation at 4 °C, the beads were washed four times with the bind-
ing buffer and proteins were applied to the SDS-polyacrylamide gel.
2.11. Statistics
Results are presented as means±S.E.M. Differences between
groups were analyzed with a one-way analysis of variance, and cor-
rections for multiple comparison were made using Tukey's multiple
comparison test. Comparisons between two groups were made
using Student's t test. Signiﬁcant differences were assumed at
Pb0.05.
3. Results
3.1. Elevation of claudin-2 expression in adenocarcinoma
NSCLC is subdivided in adenocarcinoma, squamous carcinoma,
and large cell carcinoma [24]. We examined the expression levels of
claudins in the normal and lung cancers using Lung Cancer cDNA
Array II and V. A total of 78 patients with lung cancer were evaluated
in this study. The characteristics of these patients are shown in
Table 1. The normal adjacent tissues of 12 were also examined. In
human adenocarcinoma, claudin-2 mRNA level was higher than that
in normal tissue and cancer tissues including squamous, large, andsmall cells (Fig. 1A). The patients with less than 1.0 of claudin-2
were 17, whereas the patients with more than 1.0 were 28 (Table 2).
Similar to the patients with adenocarcinoma, claudin-2 mRNA level in
Table 2
Relative claudin-2 level in the patients with adenocarcinoma.
Relative claudin-2 level No. of patients
b1.0 17
1.0–5.0 9
5.0b 19
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cells (Fig. 1B). Claudin-2 mRNA level in WA-hT cells was also higher
than that in normal tissue, but the level was one ﬁfth of A549 cells.
These results indicate that claudin-2 expression increases in lung
adenocarcinoma.0 3 6 9 12 24 (h)
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Fig. 2. Decrease in claudin-2 expression by U0126. (A) A549 cells were incubated in
the FCS-free medium (control), 5% FCS-containing medium (FCS), or FCS-free medi-
um containing 10 μM U0126 (U0126) for 24 h. Cytoplasmic lysates were immuno-
blotted with anti-claudin-1, claudin-2, E-cadherin, ZO-1, occludin and β-actin
antibodies. (B and C) Cells were incubated in the presence (closed columns) and ab-
sence (open columns) of U0126 for the period indicated. Cytoplasmic lysates were
immunoblotted with anti-claudin-1 or claudin-2 antibody. The expression of
claudin-1 and claudin-2 was expressed relative to the value in 0 h. * Pb0.05 and **
Pb0.01 compared with 0 h. NS, P>0.05.
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Fig. 3. Decrease in EGF secretion and claudin-2 expression by MMP inhibitor II.
(A) Cells were incubated in the presence and absence of 10 μM MMP inhibitor
II (MMPI) or 10 μM MMP-2 inhibitor I (MMP-2I) for the period indicated.
After being collected the medium, EGF content was measured by the assay kit.
(B) Cells were incubated in the absence (control) and presence of MMPI,
MMP-2I, 10 ng/ml EGF, or EGF plus MMPI for 24 h. Cytoplasmic lysates were
immunoblotted with anti-claudin-1 and claudin-2 antibodies. (C) Cells were in-
cubated in the absence and presence of MMPI, MMP-2I, EGF, or EGF plus MMPI
for 30 min. Cytoplasmic lysates were immunoblotted with anti-p-ERK1/2 and
ERK1/2 antibodies. ** Pb0.01 compared with control.3.2. Decrease in claudin-2 expression by U0126 in adenocarcinoma cell lines
Claudin-2 may be involved in the tumor progression of adeno-
carcinoma because it enhanced cell migration [22] and colonization
[23] in A549 cells. Therefore, we examinedwhat regulatory mechanism
is involved in the regulation of claudin-2 expression in A549 cells.
Claudin-2 protein was detected in A549 cells, but not in RERF-LC-AI,
IA-LM, andWA-hT cells (Supplementary Fig. 1). Claudin-2 level was de-
creased byU0126, aMEK inhibitor (Fig. 2A). Similarly, U0126 decreased
claudin-2 level in lung adenocarcinoma cell lines such as RERF-LC-MA
and PC-3 (Supplementary Fig. 2). The levels of claudin-1, E-cadherin,
ZO-1, occludin and β-actin were unchanged by U0126. FCS did not af-
fect the levels of these proteins. The band size of occludin was shifted
by U0126 because of its de-phosphorylated state [25]. In the absence
of FCS, claudin-2 expression increased in a time-dependent manner,
which was inhibited by U0126 (Fig. 2C). Claudin-1 expression was con-
stant for 24 h and not inhibited by U0126 (Fig. 2B). These results sug-
gest that some molecules, which activate MEK, increase claudin-2
expression under the present experimental conditions.
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pression of these proteins was expressed relative to the value in the cells transfected
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izing antibody (EGF Ab), 10 μM AG1478, or 10 μM U0126 for 30 min (A) or 24 h (B).
Cytoplasmic lysates were immunoblotted with anti-p-ERK1/2, ERK1/2, claudin-1, and
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pressing CA-MEK or DN-MEK and was immunoblotted with anti-p-ERK1/2, ERK1/2,
claudin-1, and claudin-2 antibodies. (E) Cells were incubated in the absence and pres-
ence of EGF neutralizing antibody, AG1478 or U0126 for 24 h. The cells were double sta-
ined with anti-claudin-2 (red) and ZO-1 (green) antibodies. The co-localization of
claudin-2 and ZO-1 appears yellow in the merged images. The scale bar represents
10 μm.
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EGF was secreted from A549 cells and increased in a time-dependent
manner (Fig. 3A). EGF ligands are synthesized as transmembrane precur-
sors and are cleaved to their active form bymetalloproteases [26,27]. We
examined the effect ofMMP inhibitor II, an inhibitor of MMP-1, -3, -7 and
‐9, and MMP-2 inhibitor I, an inhibitor of MMP-2, on EGF production,
claudin-2 expression, and p-ERK1/2 expression. EGF production was sig-
niﬁcantly inhibited by MMP inhibitor II, but not by MMP-2 inhibitor I.
Similarly,MMP inhibitor II decreased claudin-2 andp-ERK1/2 levelswith-
out affecting claudin-1 and ERK1/2 levels (Fig. 3B and C). We examined
the effect of MMP-3 and MMP-9 inhibitors on claudin-2 and p-ERK1/2
levels. MMP-9 inhibitor decreased claudin-2 and p-ERK1/2 levels, where-
as MMP-3 inhibitor had no effect (Supplementary Fig. 3). These results
suggest that MMP-9 is involved in the secretion of EGF, resulting in the
elevation of p-ERK1/2 and claudin-2 levels. To clarify the involvement of
EGF on the regulation of claudin-2, we examined the effect of EGF on
claudin-2 and p-ERK1/2 expression. Both claudin-2 and p-ERK1/2 levels
were decreased by MMP inhibitor II, which were recovered by EGF. Fur-
thermore, EGF increased claudin-2 level in a dose-dependent manner
(Supplementary Fig. 4). Neither MMP inhibitor II nor EGF affected
claudin-1 and p-ERK1/2 levels. These results indicate that EGF is involved
in the regulation of claudin-2 expression.
3.4. Decrease in claudin-2 expression by the inhibitors of an EGFR/MEK/
ERK pathway
To support the involvement of EGF and its signaling pathway in the
regulation of claudin-2 expression, we examined the effects of EGFR
siRNA, EGF neutralizing antibody, AG1478, an inhibitor of EGFR, and
DN-MEK. EGFR siRNA decreased p-ERK1/2 and claudin-2 levels without
affecting ERK1/2 and claudin-1 levels (Fig. 4). Similarly, EGF neutralizing
antibody, AG1478, and U0126 decreased p-ERK1/2 and claudin-2 levels
without affecting ERK1/2 and claudin-1 (Fig. 5A and B). DN-MEK de-
creased p-ERK1/2 and claudin-2 levels, whereas CA-MEK did not
(Fig. 5C and D). These results indicate that the inhibition of an EGFR/
MEK/ERK pathway decreases claduin-2 expression in A549 cells. There
raise a possibility that the inhibition of an EGFR/MEK/ERK pathwaychanges the intracellular distribution of claudin-2. Therefore, we exam-
ined the distribution of claudin-2 by immunocytochemistry. Claudin-2
was distributed in both the TJs and the intracellular compartments
1115A. Ikari et al. / Biochimica et Biophysica Acta 1823 (2012) 1110–1118under the control conditions (Fig. 5E). The red signal of claudin-2 was
merged with the green signal of ZO-1. The distribution of ZO-1 was
unchanged by EGF neutralizing antibody, AG1478, and U0126. In
contrast, the red signal of claudin-2 disappeared from both the TJs
and intracellular compartments by these treatments. These results
indicate that the inhibition of an EGFR/MEK/ERK pathway decreases
claudin-2 expression without affecting its intracellular distribution.0
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Claudin-23.5. Decrease in p-c-Fos level by the inhibition of an EGFR/MEK/ERK pathway
The activation of an EGFR/MEK/ERK pathway is involved in the
regulation of transcriptional factors such as AP-1 [28], Egr-1 [29],
and Sp-1 [30]. One putative AP-1 binding site was detected in the
5′-ﬂanking region of human claudin-2 by computer analysis using
TRANSFAC databases (Supplementary Fig. 5). The AP-1 transcrip-
tional complex is composed of at least two major factors, c-Fos and
c-Jun. The p-c-Fos and p-c-Jun were detected under the control con-
ditions (Fig. 6A). EGF neutralizing antibody, AG1478, and U0126 de-
creased p-c-Fos level, but these did not decrease p-c-Jun level
(Fig. 6B). Next, we examined the nuclear distribution of c-Fos and c-
Jun. Both c-Fos and c-Jun was detected in the nuclei under the control
conditions (Fig. 6C). EGF neutralizing antibody, AG1478, and U0126
decreased c-Fos level in the nuclei without affecting c-Jun (Fig. 6D).
These results indicate that EGF neutralizing antibody, AG1478, andCo
nt
ro
l
p-c-Fos
c-Fos
EG
F
Ab
AG
14
78
U0
1 2
6
A
p-c-Jun
c-Jun
C
c-Jun
p62
c-Fos
Co
nt
ro
l
EG
F
Ab
AG
14
78
U0
12
6
0
1.5
0.5R
el
at
iv
e 
le
ve
l
1.0
NSNS
B
Co
nt
ro
l
EG
F
Ab
AG
14
78
U0
12
6
p-c-Fos
p-c-Jun
NS
0
1.5
0.5R
el
at
iv
e 
le
ve
l
1.0
NSNS
D
Co
nt
ro
l
EG
F
Ab
AG
14
78
U 0
12
6
c-Fos
c-Jun
NS
Fig. 6. Effects of EGFR/MEK/ERK pathway inhibitors on the phosphorylation and nucle-
ar distribution of AP-1. Cells were incubated in the absence and presence of 1 μg/ml
EGF neutralizing antibody (EGF Ab), 10 μM AG1478, or 10 μM U0126 for 30 min.
(A) Cytoplasmic lysates were immunoblotted with anti-p-c-Fos, c-Fos, p-c-Jun, and
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** Pb0.01 compared with control. NS, P>0.05.U0126 decreased p-c-Fos level and the nuclear distribution of c-Fos
without affecting c-Jun.
3.6. Decrease in promoter activity of claudin-2 by AG1478 and U0126
Quantitative real‐time PCR showed that the claudin-2mRNA level is
decreased by EGF neutralizing antibody, AG1478, and U0126 (Fig. 7A).Mock
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and β-actin (Left images). The data of quantitative RT-PCR are shown in the right
graph. Claudin-1 and claudin-2 mRNA levels were normalized to β-actin level and rep-
resented as the fold increase over control. ** Pb0.01 compared with control. NS,
P>0.05. (B) The 5′-ﬂanking regions of human claudin-2 from −1031 to +37, from
−395 to +37, and from−60 to +37 were cloned into the promoter-less pGL4.10 vec-
tor. Three promoter luciferase constructs were co-transfected with the pRL-TK vector
into A549 cells. After 24 h of transfection, the cells were incubated in the absence
and presence of 10 μM AG1478 or 10 μMU0126 for 24 h. The relative promoter activity
was represented as the fold induction compared to that of the promoter‐less pGL4.10
vector (Mock). (C) The 5′-ﬂanking regions of human claudin-2 from −1031 to +37
and mutant of AP-1 binding site were cloned into the promoter-less pGL4.10 vector.
After 24 h of transfection, the cells were incubated in the absence and presence of
10 μM AG1478 or 10 μM U0126 for 24 h. Data represent means±S.E.M. of 3–4 experi-
ments. ** Pb0.01 compared with control of −1031/+37. NS, P>0.05 compared with
control of −395/+37.
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the effect of AG1478 and U0126 on the transcriptional activity of
claudin-2,wemeasured promoter activity of human claudin-2. The con-
struct of −1031/+37 showed 70-fold promoter activity compared
withmock (Fig. 7B). AG1478 and U0126 signiﬁcantly inhibited the pro-
moter activity. The deletion construct of −395/+37 showed 30-fold
promoter activity, which was not signiﬁcantly inhibited by AG1478
and U0126. The construct of −60/+37 did not show any promoter
activity. These results indicate that AG1478- and U0126-sensitive re-
gion exists between−1031 and−395. This region contains one puta-
tive AP-1 binding site. The promoter activity of the mutant of the
putative AP-1 binding site was half of that of wild‐type (Fig. 7C). Fur-
thermore, it was not inhibited by AG1478 and U0126. These results in-
dicate that AP-1 binding site is involved in the regulation of promoter
activity of claudin-2 and both AG1478 and U0126 inhibits the reaction
in AP-1 binding site.
3.7. Interaction of AP-1 with claudin-2 promoter
The introduction of c-Fos or c-Jun siRNA decreased the expression of
c-Fos and c-Jun, respectively (Fig. 8A). Both siRNAs decreased claudin-2
expression without affecting claudin-1 expression. In the ChIP assay, a
primer pair of –935S/−782A containing AP-1 binding site showed pos-
itive PCR signals in the control cells using anti-c-Fos or c-Jun antibody
(Fig. 8B). In contrast, a primer pair of −1538S/−1387A, which am-
pliﬁes a sequence about 500 bases upstream from AP-1 binding site,
showed no positive signals. In the U0126- or AG1478-treated cells, no
PCR signals were observed using anti-c-Fos or c-Jun antibody. Using
goat IgG, neither −935S/−782A nor −1538S/−1387A produced a
PCR signal. Next, we performed an ABCD assay using biotin conjugat-
ed double-strand oligonucleotides that contain wild-type or mutant
AP-1 binding site. Wild-type AP-1 binding site bound to both c-Fos
and c-Jun (Fig. 8C). In contrast, mutant AP-1 binding site bound to
neither c-Fos nor c-Jun. These results indicate that c-Fos and c-Jun
bind to the promoter region containing AP-1 binding site of human
claudin-2.
4. Discussion
Claudin-2 mRNA is not expressed in normal lung epithelia [18,19],
but its expression is increased in human lung adenocarcinoma [31].
We also found that claudin-2 expression in lung adenocarcinoma
and A549 cells is higher than that in normal tissue and other lung car-
cinomas (Fig. 1). Claudin-2 knockdown decreases cell migration in
A549 cells [22], whereas claudin-2 overexpression increases A549
cell colonization [23]. Claudin-2 may be involved in lung adeno-
carcinoma development. Similar to lung adenocarcinoma, claudin-2
expression increases in colonic [32] and gastric [33] cancers. Forced
claudin-2 expression in colon cancer cells increases tumor growth in
vivo. In contrast, claudin-2 expression decreases in breast carcinoma
[34] and prostate adenocarcinoma [35]. These reports suggest that
claudin-2 expressionmay involve organ speciﬁcity and increased expres-
sion of claudin-2 participates in lung, colonic, and gastric carcinogenesis.
The regulatory mechanism of claudin-2 expression has been clar-
iﬁed using renal and intestinal epithelial cells. Claudin-2 expression is
down-regulated by protein kinases including ERK1/2 [36,37], small
GTPase RhoA, and c-Jun NH2-terminal kinase [38] in renal Madin–
Darby canine kidney (MDCK) II cells. In contrast, the expression is
up-regulated by transcriptional factors including cdx1, cdx2, HNF-
1α and GATA-4 in intestinal HT-29, Caco-2, or HIEC-6 cells. It was un-
known what transcriptional factors are involved in the regulation
of claudin-2 expression and what mechanisms are involved in the
regulation of the transcriptional factors of claudin-2 in lung adeno-
carcinoma. Lung adenocarcinoma shows negative or only focal cdx2
expression [39]. GATA-4 expression is absent in various lung cancer
cell lines including A549 cells [40]. Therefore, other transcriptionalfactors may be involved in the regulation of claudin-2 expression
in A549 cells. Peter et al. [23] reported that EGF increases claudin-
2 expression in A549 cells, which is inhibited by a MEK inhibitor.
However, it is unknown what regulatory mechanism is involved in
the basal expression of claudin-2 and what transcriptional factor
is involved in the regulation of claudin-2 in A549 cells. Here we
found that claudin-2 expression is up-regulated by the secreted
1117A. Ikari et al. / Biochimica et Biophysica Acta 1823 (2012) 1110–1118EGF and its transcriptional activity is activated by a EGFR/MEK/ERK/
c-Fos pathway. The activation of MEK have opposite effects on
claudin-2 expression in A549 and MDCK II cells. The elucidation of
the regulatory mechanism of EGF on claudin-2 expression in
MDCK II cells may be also useful to clarify the mechanism of lung
adenocarcinoma.
Lung cancer cells secrete various growth factors including EGF,
transforming growth factor (TGF) α, TGF β-2, and insulin-like growth
factor, and basic ﬁbroblast growth factor [41,42]. The EGF precursor
(pro-EGF) is present as its membrane associated highmolecular weight
precursor exposed at the cell surface. In various epithelial cells, different
processing of pro-EGF is involved in the release of soluble EGF. EGF is se-
creted by a serine protease in the salivary gland [43], mammary gland
[44] and the kidney, and zinc dependent metalloprotease in CHO and
HMEC cells [26,27]. Heparin-binding EGF is secreted by MMP in lung
A431 cells [45], but it was unknown whether EGF is secreted by same
MMP in A549 cells. We found that EGF is secreted from A549 cells by
MMP, resulting in the activation of an EGFR/MEK/ERK pathway and
the increase in claudin-2 expression. Claudin-2 expression was de-
creased by MMP-9 inhibitor, but not by MMP-3 inhibitor (Supplemen-
tary Fig. 3) and serine protease inhibitor (data not shown). We do not
know whether MMP-1 and ‐7 are involved in the secretion of EGF in
A549 cells, but we suggest that EGF may be secreted by MMP-9,
resulting in the up-regulation of claudin-2 expression.
The deletion or mutation of putative AP-1 binding site decreased
the promoter activity of human claudin-2 to the same extent as in
the inhibitors of an EGFR/MEK/ERK pathway. AP-1 functions as a
dimer in the form of c-Fos/c-Jun or c-Jun/c-Jun. The nuclear localiza-
tion of c-Fos was decreased by EGF antibody, AG1478, and U0126,
whereas that of c-Jun was unaffected by these drugs (Fig. 6C and
D). However, the involvement of c-Jun was demonstrated by three
experiments. (1) c-Jun siRNA decreased claudin-2 expression similar
to c-Fos siRNA (Fig. 8A). (2) ChIP assay showed that c-Fos and c-Jun
are bound to the promoter region containing AP-1-binding site
under the control conditions, and the association was inhibited by
AG1478 and U0126 (Fig. 8B). (3) ABCD assay showed that c-Jun is
bound towild-typeAP-1 binding site, whereas it is not bound tomutant
AP-1 binding site (Fig. 8C). We suggest that the dimer of c-Fos/c-Jun is
bound to AP-1 binding site of human claudin-2 promoter and increases
claudin-2 expression.
Vicent et al. [46] reported that there is a strong statistical correlation
between nuclear and cytoplasmic p-ERK1/2 staining and advanced
stages of NSCLC. Patients with a positive p-ERK1/2 cytoplasmic staining
had a lower survival. Furthermore, c-Fos and c-Jun expressions are
down-regulated in long-term survivors with NSCLC compared to
those in short-term survivors [47]. Our data showed that claudin-2 ex-
pression is up-regulated by p-ERK1/2, c-Fos, and c-Jun. Claudin-2 may
affect survivorship of NSCLC.
In conclusion, we found that claudin-2 expression in lung adenocar-
cinoma is higher than that in normal tissue and lung cancers including
squamous, large, and small cells. EGF was secreted from A549 cells by
MMP and increased claudin-2 expression mediated via the activation
of an MEK/ERK/c-Fos pathway. Claudin-2 up-regulates cell migration
and colonization in A549 cells. Claudin-2 may become a novel marker
for lung adenocarcinoma and its regulatory pathway may become a
novel target for anticancer drugs.
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